Understand the source comparison
Peptides for Andropause Research: Mechanism Comparison
CJC-1295 DAC GHRH receptor agonist (pituitary) 6–8 days Sustained GH pulsatility restoration IGF-1 elevation, lean mass gain, bone density Best for anabolic signaling studies; requires weekly dosing to avoid receptor desensitisation PT-141 MC3R/MC4R agonist (h
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 DAC
- GHRH receptor agonist (pituitary)
- 6–8 days
- Sustained GH pulsatility restoration
- IGF-1 elevation, lean mass gain, bone density
- Best for anabolic signaling studies; requires weekly dosing to avoid receptor desensitisation
- PT-141
- MC3R/MC4R agonist (hypothalamus)
- 2–3 hours
- Central libido restoration independent of vascular function
- Sexual desire score, arousal latency
- Addresses desire deficit when TRT alone fails; 40% experience transient nausea
- MOTS-C
- Mitochondrial-nuclear signaling
- 4–6 hours
- Insulin sensitivity and mitochondrial biogenesis
- HOMA-IR, mitochondrial density (biopsy)
- Targets metabolic dysfunction separate from hormonal correction; short reconstituted stability
- Kisspeptin-10
- GnRH pathway modulator (hypothalamus)
- 20–30 minutes
- Hypothalamic-pituitary axis reactivation
- LH pulse amplitude, endogenous testosterone
- Ultra-short half-life requires continuous infusion or frequent bolus; used to test upstream axis function